Our Science


ACEA leverages its drug discovery platform, unique expertise in real-time cell analysis, and a 1 million+ compound library to evaluate and identify compounds with “best-in-class” potential. Our unique drug discovery platform of small and large molecules has generated multiple novels and proprietary new chemical entities currently at preclinical and clinical stage development for the treatment of cancer and autoimmune diseases.

Cancer Research:


In recent years, our understanding of diseases has been transformed. For example, tumors sharing the same origin are now known to comprise an array of diseases with varying molecular ‘fingerprints’ which result in different disease characteristics and responsiveness to treatments. Together with technology advances, targeted therapy is a new generation of precision medicine meeting individual patient’s need.

Embracing precision medicine, ACEA leverages its drug discovery platform, unique expertise in real-time cell analysis, a 1 million+ compound library, and computer aided design to identify drug candidates with “best-in-class” potential. Multiple novel and proprietary new chemical entities currently at preclinical and clinical stage development for the treatment of cancer and autoimmune diseases.

For more information on our on-going pre-clinical and clinical programs, please visit our pipeline.

Targeted Therapy:

  • Small molecule treatments work inside the cell
  • Kills tumor cells while preserving healthy cells
  • Tend to be more efficacious than chemotherapy with fewer drug-related side effects
  • Biomarker-driven patient selection increases the likelihood of responding to therapy

Autoimmune Disease Research:


The cause of most autoimmune diseases remains unknown. Several external and environmental factors such as a person’s gene, infections, and other environmental factors may play a role in disease development. ACEA research focuses on identifying treatments that can block or suppress genes known to cause autoimmune diseases.

Small Molecule Antiviral Research (COVID-19):


COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is a contagious and potentially fatal respiratory disease which poses a serious threat to global public health. ACEA research focuses on identification and development of small heterocyclic molecules which are orally available for the treatment of virus infection diseases, especially COVID-19.


For more information on our on-going pre-clinical and clinical programs, please visit our pipeline.